This week, atai Life Sciences (ATAI), the largest pureplay clinical-stage psychedelic company in our index, just reported financial results for the first quarter of 2022 and provided a business update.
What’s the latest news in atai’s drug pipeline? And how much cash did the company burn this quarter compared to the last?
Tune in to our latest video breakdown below discussing the results, investor reactions, technical price analysis, and more.
Our PRO Series host, Adam Tubero, also gives his perspective on some of the non-psychedelic Drugs in atai’s pipeline such as Etifoxine (GABA) and Kures-101 (Mitragynine).